Try our beta test site
7 studies found for:    lymphoma OR CLL | Entospletinib
Show Display Options
Rank Status Study
1 Not yet recruiting Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
Conditions: Anemia;   B-Cell Prolymphocytic Leukemia;   Fatigue;   Fever;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Hairy Cell Leukemia;   Lymphadenopathy;   Lymphocytosis;   Lymphoplasmacytic Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Night Sweats;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Small Lymphocytic Lymphoma;   Richter Syndrome;   Splenomegaly;   Thrombocytopenia;   Weight Loss
Interventions: Drug: Entospletinib;   Other: Laboratory Biomarker Analysis;   Biological: Obinutuzumab;   Other: Pharmacological Study
2 Recruiting Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Tirabrutinib;   Drug: Entospletinib;   Drug: Obinutuzumab
3 Active, not recruiting Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
Condition: Non-Hodgkin Lymphoma
Interventions: Drug: ENTO;   Drug: VCR
4 Completed Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
Conditions: Chronic Lymphocytic Leukemia;   Mantle Cell Lymphoma;   Diffuse Large B-cell Lymphoma;   Indolent Non-Hodgkin's Lymphoma
Interventions: Drug: Entospletinib;   Drug: Idelalisib
5 Recruiting Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies
Conditions: Chronic Lymphocytic Leukemia;   Mantle Cell Lymphoma;   Diffuse Large B-cell Lymphoma;   Non-FL Indolent Non-Hodgkin's Lymphoma;   Follicular Lymphoma
Interventions: Drug: Entospletinib;   Drug: Entospletinib SDD
6 Completed A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Treatment A;   Drug: Treatment B;   Drug: Treatment C;   Drug: Treatment D;   Drug: Treatment E;   Drug: Treatment F;   Drug: Treatment G;   Drug: Treatment H;   Drug: Treatment I;   Drug: Treatment J
7 Recruiting Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoid Leukemia (ALL)
Condition: Acute Lymphoid Leukemia
Interventions: Drug: Entospletinib;   Drug: VCR;   Drug: Dexamethasone;   Drug: CNS Prophylaxis

Study has passed its completion date and status has not been verified in more than two years.